The IDE Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the IDE gene in the Jurkat human T lymphocyte line. This heterogeneous pool of gene-edited cells offers a robust loss-of-function model for investigating the physiological roles of insulin-degrading enzyme (IDE/insulysin). The polyclonal format provides a versatile system that captures a range of editing events without clonal selection, supporting studies where population-level phenotypes are prioritized. By ablating IDE function, researchers can explore the consequences of impaired peptide hormone degradation and altered proteostasis in a relevant immune cell context.
Jurkat cells are an immortalized human T lymphocyte line originally derived from a patient with acute T cell leukemia. These suspension cells are widely employed in immunology, cancer biology, and signal transduction research due to their well-characterized T cell receptor signaling, robust proliferation, and ease of genetic manipulation. The Jurkat background enables dissection of signaling cascades downstream of various receptors, including those responsive to insulin-like signals, and serves as a platform for studying metabolic regulation in lymphocytes. This model system is particularly valuable for examining how IDE-mediated proteolytic activity intersects with T cell function and metabolic homeostasis.
The IDE gene encodes a zinc metallopeptidase that critically regulates levels of insulin, glucagon, and amyloid-beta peptides through proteolytic degradation. IDE functions downstream of PPAR?? and is transcriptionally regulated by insulin and glucagon. The enzyme interacts directly with substrates such as insulin and amyloid-beta, and associates with ubiquitin and proteasome subunits, linking hormone catabolism to the ubiquitin-proteasome system. In the insulin signaling pathway, IDE-mediated cleavage of insulin attenuates activation of the insulin receptor (INSR), IRS1, and AKT, ultimately controlling GLUT4 translocation. Consequently, IDE knockout leads to sustained insulin signaling and may disrupt the balance of other peptide hormones, impacting cellular metabolism and proteostasis networks.
In Jurkat T cells, IDE knockout is expected to impair degradation of insulin and possibly other substrates, resulting in prolonged insulin receptor activation. This sustained signaling can alter downstream pathways involving AKT and mTOR, influencing T cell metabolism, proliferation, and cytokine responses. Given the emerging role of insulin signaling in immune cell function, this model provides a powerful tool to examine how IDE-dependent proteostasis shapes lymphocyte metabolic adaptation and activation. The knockout may also sensitize cells to amyloid-beta accumulation, offering insights into neuroimmune interactions relevant to Alzheimer’s disease pathology within an immune cell context.
This IDE knockout cell product is suitable for a broad spectrum of research applications, including mechanistic studies of insulin and amyloid-beta clearance, drug screening for IDE modulators, and functional dissection of hormone-regulated signaling in T cells. Researchers can employ assays such as Western blotting and RT-qPCR to confirm IDE disruption and assess downstream target expression, insulin degradation enzymatic assays to quantify proteolytic activity, and flow cytometry to monitor Jurkat activation markers or metabolic indicators. Immunofluorescence can be used to visualize subcellular localization changes, while sequencing of the IDE locus verifies editing. For further details, please contact Ascent Research.
